BRAIN ATTACK! ‘25

Saturday, May 3, 2025, 7:00 AM - 5:00 PM, UCLA Carnesale Commons, Los Angeles, CA

The UCLA Comprehensive Stroke Center presents its annual Brain Attack symposium to review the practical, clinical aspects of stroke prevention, diagnosis, and treatment. The course will cover stroke risk factors, diagnostic testing, and medical and interventional therapy.

Intravenous thrombolysis and neuroendovascular thrombectomy are highly effective techniques for treatment of acute ischemic stroke. The results of recent studies indicate that these reperfusion therapies are beneficial up to 4.5-6 hours after symptom onset in most patients, and up to 24 hours in imaging-selected patients. A highly coordinated team approach is required to provide these treatments safely and effectively.

Neuroimaging techniques are playing an increasingly important role in the evaluation of stroke patients. Faculty will provide an in-depth discussion of innovative MR and CT techniques.

In-Person Registration

In-Person fee Includes course registration, access to on-line course materials, continental breakfast, break refreshments, and lunch.

• $225 Physicians, Nurses and Allied Health

• $150 UC Faculty/Staff

Virtual Registration

• $150 Physicians, Nurses and Allied Health

• $100 UC Faculty/Staff

 

Recharge Payment Information

Registration payment can be submitted via the Interdepartmental recharge system.
For more details, please refer to document here: Recharge Information

Refunds

Cancellations must be received via email to [email protected] by April 12, 2025 and will be subject to a $75 processing fee. No refunds will be granted after that date. If, for any reason, the course must be cancelled, discontinued, or rescheduled a full refund will be provided.

Course Recording

All registrants (live or virtual) will be provided the opportunity to review recorded sessions up to 3 weeks following the conference.

The recorded sessions are not approved for Continuing Education (CE) credit.

 

1. Summarize recent advances in the treatment of atrial fibrillation.
2. Describe recent advances in endovascular treatment of carotid bulb disease and management of intracranial atherosclerosis.
3. Employ advanced brain imaging in diagnosis of ischemic and hemorrhagic stroke.
4. Summarize recent developments in endovascular treatment of acute ischemic stroke and management of the post-thrombectomy patient.
5. Employ recent developments in management of intracerebral and subdural hemorrhage.
6. Discuss natural history of cerebral aneurysms and patient selection for treatment.
7. Outline endovascular and surgical treatment options for intracranial aneurysms.
8. Describe the benefits and components of a specialized stroke rehabilitation program.

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

AMA PRA Category 1 Credits™ (7.50 hours), Non-Physician Attendance (7.50 hours)

Location

UCLA Carnesale Commons
Palisades Ballroom

251 Charles E. Young Drive, West
Los Angeles, CA 90095

Self Parking & Direction

Parking is available at Sunset Village (SV) parking structure located at 200 De Neve Dr., Los Angeles, CA. Parking fee is $15. Guests will be able to pay for parking at the pay-by-space machines located in the Sunset Village (SV) parking structure. Directional signs will be provided to guide you to the program.

Mitigation of Relevant Financial Relationships

The Accreditation Council for Continuing Medical Education (ACCME), Standards for Integrity and Independence mandates that the accreditation manages all identified relevant financial relationship(s) before the program and adequately discloses relationships to learners. The David Geffen School of Medicine at UCLA adheres to the ACCME Standards for Integrity and Independence in accredited continuing education.

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated.

Saturday, May 3, 2025

W9 Form Exhibit at this Event